The Main Sequence of Explosive Solar Active Regions: Comparison of Emerging and Mature Active Regions

For mature active regions, an active region s magnetic flux content determines the maximum free energy the active region can have. Most Large flares and CMEs occur in active regions that are near their free-energy limit. Active-region flare power radiated in the GOES 1-8 band increases steeply as the free-energy limit is approached. We infer that the free-energy limit is set by the rate of release of an active region s free magnetic energy by flares, CMEs and coronal heating balancing the maximum rate the Sun can put free energy into the active region s magnetic field. This balance of maximum power results in explosive active regions residing in a "mainsequence" in active-region (flux content, free energy content) phase space, which sequence is analogous to the main sequence of hydrogen-burning stars in (mass, luminosity) phase space

Free Magnetic Energy and Coronal Heating

Previous work has shown that the coronal X-ray luminosity of an active region increases roughly in direct proportion to the total photospheric flux of the active region's magnetic field (Fisher et al. 1998). It is also observed, however, that the coronal luminosity of active regions of nearly the same flux content can differ by an order of magnitude. In this presentation, we analyze 10 active regions with roughly the same total magnetic flux. We first determine several coronal properties, such as X-ray luminosity (calculated using Hinode XRT), peak temperature (calculated using Hinode EIS), and total Fe XVIII emission (calculated using SDO AIA). We present the dependence of these properties on a proxy of the free magnetic energy of the active regio

Integrating Watershed Management Across the Urban–Rural Interface: Opportunities for Extension Watershed Programs

Urban–rural partnerships are increasingly viewed as a critical component of efforts to improve water quality at the watershed scale. We present an opportunity for such partnerships, using an off-site best management practice (BMP) program developed between the City of Wichita and agricultural producers in the Little Arkansas River Watershed of south-central Kansas as an example. We highlight the critical role of Extension specialists in developing this and similar programs, the success of which hinges on targeted BMP implementation and relationships with agricultural producers

Neonatal Safety Information Reported to the FDA During Drug Development Studies.

BACKGROUND: Relatively few neonatal drug development studies have been conducted, but an increase is expected with the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA). Understanding the safety of drugs studied in neonates is complicated by the unique nature of the population and the level of illness. The objective of this study was to examine neonatal safety data submitted to the FDA in studies pursuant to the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) between 1998 and 2015. METHODS: FDA databases were searched for BPCA and/or PREA studies that enrolled neonates. Studies that enrolled a minimum of 3 neonates were analyzed for the presence and content of neonatal safety data. RESULTS: The analysis identified 40 drugs that were studied in 3 or more neonates. Of the 40 drugs, 36 drugs received a pediatric labeling change as a result of studies between 1998 and 2015, that included information from studies including neonates. Fourteen drugs were approved for use in neonates. Clinical trials for 20 of the drugs reported serious adverse events (SAEs) in neonates. The SAEs primarily involved cardiovascular events such as bradycardia and/or hypotension or laboratory abnormalities such as anemia, neutropenia, and electrolyte disturbances. Deaths were reported during studies of 9 drugs. CONCLUSIONS: Our analysis revealed that SAEs were reported in studies involving 20 of the 40 drugs evaluated in neonates, with deaths identified in 9 of those studies. Patients enrolled in studies were often critically ill, which complicated determination of whether an adverse event was drug-related. We conclude that the traditional means for collecting safety information in drug development trials needs to be adjusted for neonates and will require the collaboration of regulators, industry, and the clinical and research communities to establish appropriate definitions and reporting strategies for the neonatal population

X-33 Metallic TPS Tests in NASA-LaRC High Temperature Tunnel

Conclusions The first series of metallic TPS tests in the NASA-LaRC Mach 7 High Temperature Tunnel has been completed. Additional testing is 'in progress and shall provide data for off-design configurations for the metallic TPS. The available data are being analyzed and being used to correlate analytical models to be used for X-33 flight design analysis. The final paper shan present additional data from these tests and comparisons between the data and analytical predictions

Magnetic Untwisting in Most Solar X-Ray Jets

If TypeII spicules are made like Xray jets by granulesize emerging bipoles, then they plausibly power the quiet corona and solar wind